Connect your AI

Exagen Inc. XGN Change in Other Assets

Change in Other Assets at other companies

Labcorp HoldingsLH

-$4M+91.1%

Vor BiopharmaVOR

$6.36M+2,653%

Avalo TherapeuticsAVTX

-$228K+90.9%

Jade Biosciences, Inc. Common StockJBIO

$1.86M+765%

Biodesix, Inc.BDSX

-$19K-26.7%

Janux TherapeuticsJANX

$1.34M+1,552%

Other financials

Income statement

Revenue$17.3M+11.7%

Gross profit$10.2M+11.9%

Operating income-$3.4M-1.5%

Net income-$4.0M-5.7%

EPS (diluted)-$0.17+15.0%

Balance sheet

Cash & equivalents$21.7M+90.6%

Total debt$27.1M+15.8%

Total equity$14.4M+125%

Total assets$52.0M+28.9%

Cash flow

Operating cash flow-$10.4M+2.4%

CapEx$228.0K+102%

Free cash flow-$10.6M+1.3%

Valuation

Market cap$112.34M-26.5%

Enterprise value$117.78M-20.3%

P/S1.6×-1.0×

Profitability

Gross margin58.3%-1.0pp

Operating margin-20.6%-2.9pp

Net margin-29.5%+2.5pp

FCF margin-27.5%—

Returns & leverage

Return on equity-193.6%+355pp

Debt / equity1.9×-1.8×

Current ratio3.5×+1.1×

Where this comes from

Reported directly by Exagen Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentAssets.

The official record: Exagen Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exagen Inc.'s change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Exagen Inc.'s change in other assets?: Exagen Inc. (XGN) reported change in other assets of -$172K in Q1 2026.
How has Exagen Inc.'s change in other assets changed year-over-year?: Exagen Inc.'s change in other assets decreased by 138.9% year-over-year, from -$72K to -$172K.
What does change in other assets mean?: Change in miscellaneous assets affecting operating cash flow.